Compare DexCom, Inc. (DXCM) vs Google Inc (GOOG) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

GOOG trades at $357.33, up 1.9% today, with a bullish technical signal and strong support at $353. The company shows robust fundamentals with 2025 revenue of $402.84B, net income of $132.17B, and a net margin of 32.8%. Recent earnings beats and a consensus analyst price target of $457.50 highlight positive momentum, while news includes Warren Buffett's endorsement and strategic AI partnerships.

Outlook remains positive driven by earnings growth and AI expansion, but risks include regulatory fines and competitive pressures. Wall Street sentiment is strongly bullish with 87% buy ratings, suggesting upside potential, though investors should monitor execution and macroeconomic factors.